Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

IGC Pharma, Inc. Common Stock (NY:IGC)

0.3474 +0.0060 (+1.76%)
Official Closing Price Updated: 8:00 PM EDT, Aug 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about IGC Pharma, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
IGC Pharma Reports Third Quarter Fiscal 2024 Results
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Reports Data from Preclinical Studies Indicating Proprietary Drug Candidate Reduces Agitation in Alzheimer’s Mouse Model
Via Investor Brand Network
Topics Artificial Intelligence
IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Reports Data Showing Proprietary Drug Candidate TGR-63 Reduces Plaque in Alzheimer’s
Via Investor Brand Network
Topics Artificial Intelligence
Why IGC Pharma Stock Is Moving Higher
IGC Pharma highlighted data from a trial in which the group treated with TGR-63 showed a 78% and 85% reduction in the cortical and hippocampal amyloid load, respectively, reaffirming its potential to... 
Via Benzinga
IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’s
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Activates ClinCloud in Phase 2b Alzheimer’s Trial
Via Investor Brand Network
Topics Artificial Intelligence
IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s Trial
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Receives ‘Milestone’ Patent for Drug Formulation Used to Treat Agitation in Alzheimer’s
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer’s
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) to Participate at Biotech Showcase and BioPartnering @ JPM
Via Investor Brand Network
Topics Artificial Intelligence
IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Partners with Prominent Center to Integrate AI into Clinical Trials
Via Investor Brand Network
Topics Artificial Intelligence
IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials
From IGC Pharma, Inc.
Via Business Wire
AI And THC: IGC Pharma Teams Up With Colombian University For Alzheimer's Treatment Research
IGC Pharma partners with University of Los Andes, to leverage AI for improving Alzheimer's disease treatment and clinical trial efficiency. 
Via Benzinga
Topics Artificial Intelligence
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Enters Strategic Collaboration to Advance AI Initiatives
Via Investor Brand Network
Topics Artificial Intelligence
IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Releases Q2 2024 Financial, Corporate Report
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
IGC Pharma Reports Second Quarter Fiscal 2024 Results
From IGC Pharma, Inc.
Via Business Wire
Cannabis Based Pain Relief Solution Receives European Patent Approval
IGC Pharma, Inc. (NYSE American: IGC) has been granted European Patent No. 3193862 by the European Patent Office for its innovative "Cannabinoid Composition and Method for Treating Pain." 
Via Benzinga
Topics Cannabis Intellectual Property
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Cannabinoid-Based Topical Pain-Relief Treatment Receives European Patent
Via Investor Brand Network
Topics Intellectual Property
IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy
From IGC Pharma, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
420 with CNW — Study Suggests Marijuana Users Are Less Predisposed to Type 2 Diabetes
Via Investor Brand Network
Topics Cannabis
420 with CNW — Study Suggests Marijuana Users Are Less Predisposed to Type 2 Diabetes
Via CannabisNewsWire
Topics Cannabis
BioMedNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Announces Results of Annual Meeting
Via Investor Brand Network
Topics Regulatory Compliance
IGC Announces Results of its 2023 Annual Stockholders Meeting
From IGC Pharma, Inc.
Via Business Wire
420 with CNW — AMA Study Finds Marijuana Smoking Viewed as Safer Than Cigarette Smoking
Via CannabisNewsWire
Topics Cannabis
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.